CST1 Protein

Produktnummer ABIN2712804

Produktdetails

Target: CST1 (Cystatin SN (CST1))

Protein-Typ: Recombinant

Spezies: Human

Quelle: HEK-293 Cells

Applikation: Antibody Production (AbP), Standard (STD)

Produktmerkmale:

• Recombinant human Cystatin-SN protein expressed in HEK293 cells.
• Produced with end-sequenced ORF clone

Reinheit: > 95 % as determined by SDS-PAGE and Coomassie blue staining

Endotoxin-Niveau: < 0.1 EU per μg protein as determined by LAL test

Anwendungsinformationen

Applikationshinweise: Recombinant human proteins can be used for:
Native antigens for optimized antibody production
Positive controls in ELISA and other antibody assays

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: Lyophilized from a 0.2 μM filtered solution of 20 mM MES, 150 mM NaCl, pH 5.5. Stable for at least 6 months from date of receipt under proper storage and handling conditions.

Lagerung: -80 °C

Informationen zur Lagerung: Store at -80°C. Thaw on ice, aliquot to individual single-use tubes, and then re-freeze immediately. Only 2-3 freeze thaw cycles are recommended.

Antigendetails

Target: CST1 (Cystatin SN (CST1))

Andere Bezeichnung: Cystatin-Sn (CST1 Produkte)

Hintergrund: The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences. Some of the members are active cysteine protease inhibitors, while others have lost or perhaps never acquired this inhibitory activity. There are three inhibitory families in the superfamily, including the type 1 cystatins (stefins), type 2 cystatins and the kininogens. The type 2 cystatin proteins are a class of cysteine proteinase inhibitors found in a variety of human fluids and secretions, where they appear to provide protective functions. The cystatin locus on chromosome 20 contains the majority of the type 2 cystatin genes and pseudogenes. This gene is located in the cystatin locus and encodes a cysteine proteinase inhibitor found in saliva, tears, urine, and seminal fluid.

Molekulargewicht: 15.4 kDa

NCBI Accession: NP_001889